Navigation Links
Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy

ditional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of the final results of the RAPID clinical study of pixantrone to have the same or similar results to the interim analysis, or the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma or other cancers, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10- K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter


its forward-looking statements whether as a result of new information, future

events, or otherwise.


    Media Contact:

    Dan Eramian

    T: 206.272.4343

    C: 206.854.1200


    Susan Callahan

    T: 206.272.4472

    F: 206.272.4434

    E: 

    http://www.cticseattle.com/media.htm


    Investors Contact:

    Leah Grant

    T: 206.282.7100

    F: 206.272.4434

    E: 

    http://www.cticseattle.com/investors.htm


    Medic
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
4. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
5. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
6. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
7. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
10. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
11. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
Post Your Comments:
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... in Santa Ana, California is a ... market for which is estimated at $22 billion in the ... includes the use of FDA-approved Naltrexone in a specially compounded ... (excluding Australia and New ...
(Date:3/27/2015)... Across the global healthcare landscape, the Medical ... development, market education, and regulatory compliance. As emerging markets ... is expected to increase in prominence and follow the ... to research by benchmarking firm, Best Practices, LLC, all ... Medical Affairs. Among companies in India ...
(Date:3/27/2015)... March 27, 2015  The quality function within the ... products meet quality standards at every stage of the ... quality leaders also have the challenge of balancing quality ... Those who don,t effectively balance these priorities risk funding ... marketplace failure and regulatory scrutiny. For the ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2
... MOUNTAIN VIEW, Calif., Feb. 28, 2011 VIVUS, ... to the development and commercialization of novel therapeutic products, today ... and year ended December 31, 2010. ... development program, we successfully completed the two-year SEQUEL study, an ...
... The staffs of Chiltern International Limited (Chiltern), a global ... 25 year mark of their successful collaboration in Drug ... have worked together using a validated and regulatory accepted ... assessment of drug phototoxicity. The history of this collaboration ...
Cached Medicine Technology:VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 2VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 3VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 4VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 5VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 6VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 7Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years 2Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years 3
(Date:3/28/2015)... 28, 2015 How best to treat ... field in orthopaedic medicine. While diagnostic hip injections are ... the pain etiology, research presented today at the American ... Day suggests that pain relief from this diagnostic injection ... , “Our study looked to assess if the ...
(Date:3/28/2015)... 28, 2015 Early surgery may not ... V AC joint injuries, according to new research from ... the American Orthopaedic Society for Sports Medicine’s ( AOSSM ... faster when surgery was not performed. , The final ... surgical treatment and 17 receiving non-surgical therapy. Of the ...
(Date:3/28/2015)... Andrew Hawley of Vintage Rock Posters Inc., has announced ... Who and the Doors played together at the Singer Bowl ... Hawley, “The Who toured the United States heavily from 1967 ... the most famous Who poster was a poster created to ... August 2, 1968 at the Singer Bowl in Flushing, New ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Aureus ... healthcare staffing, including physical therapy jobs, has announced ... the Ohio Physical Therapy Association Annual Conference to ... Columbus Downtown Hotel in Columbus, OH. , ... opportunities, and exhibits with products and services. ...
(Date:3/28/2015)... March 28, 2015 The "Petrick ... of sustainable health. After 18 years of research and ... professional UFC contenders, Dr. Jon Petrick is excited to ... Just some of the immediate benefits of this radical ... increased levels of strength of the immune system, faster ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2
... Joins International Observance To Draw Attention To "The Sneak Thief ... In an effort to combat one of the leading causes ... Glaucoma Patient Organization have set March 12, 2009, as the ... be marked by awareness and educational events organized by eye ...
... Services, Inc. (NYSE: WST ) announced today ... before the market opens on Thursday, February 19, 2009 ... the results and business expectations at 9:00 a.m. Eastern ... or (210)839-8398. The passcode is WST.A live broadcast of ...
... of New York Health AdvisoryNEW YORK, Feb. 12 ... children in New York City, according to the United ... research suggests that there are many causes for asthma ... immune system changes that result from the presence, or ...
... Available to a Wider Medical Market through Nation,s Largest GPO ... ... Medical Devices, an industry leader in infection control products, has recently ... largest and most respected GPOs, or group provider organizations. As Novation ...
... of image management services for endovascular imaging and ... made a contribution to the Open the Pathway ... the Pathway is an initiative that was established ... commitment to vascular treatment planning, post-operative patient outcomes ...
... Dynatronics Corporation (Nasdaq: DYNT ) will release ... December 31, 2008 during the morning of Friday, February ... investors later that day at 1:00 p.m. ET to ... periods. Those interested in participating should call 800-839-9416 ...
Cached Medicine News:Health News:World Glaucoma Day Set For March 12, 2009 2Health News:World Glaucoma Day Set For March 12, 2009 3Health News:World Glaucoma Day Set For March 12, 2009 4Health News:West to Host 2008 Fourth Quarter Conference Call 2Health News:Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma 2Health News:Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma 3Health News:Inviro Medical Devices Is Awarded a Three Year Contract with Leading GPO Novation 2Health News:M2S, Inc. Makes Contribution to American Vascular Association 2Health News:M2S, Inc. Makes Contribution to American Vascular Association 3
... sophisticated research tool that allows to see ... is being stimulated. Besides it also includes ... to switch between the pupil picture and ... This system is especially suited for animal ...
The only air-based esthesiometer with a database of normal sensation on the cornea. May have application to the measurement of normal-tension glaucoma....
Kelly Punches...
... The CSV- lOOOHGT instrument provides standardized glare testing. ... Vectorvision test faces for the evaluation of glare ... is precisely calibrated to simulate two on-coming halogen ... feet. The glare level can be adjusted to ...
Medicine Products: